Ardelyx Announces Changes to the Executive Leadership Team
Ardelyx (NASDAQ:ARDX) announced significant changes to its Executive Leadership Team. The company appointed Edward Conner, M.D. as Chief Medical Officer, bringing over 20 years of experience in clinical development and regulatory approval. John Bishop, Ph.D. was named to the newly created position of Chief Technical Operations Officer, contributing 30 years of technical operations expertise.
Additionally, Justin Renz, the current Chief Financial and Operations Officer, will be departing the company by the end of 2025 or upon the successful transition to a new CFO. These changes are part of Ardelyx's strategic positioning for its next growth phase, following recent appointments including Mike Kelliher as CBO, Laura Williams as CPO, and Jamie Brady as CHRO.
Ardelyx (NASDAQ:ARDX) ha annunciato importanti cambiamenti nel suo Team di Leadership Esecutiva. La societ脿 ha nominato Edward Conner, M.D. come Chief Medical Officer, portando oltre 20 anni di esperienza nello sviluppo clinico e nell'approvazione regolatoria. John Bishop, Ph.D. 猫 stato nominato nel nuovo ruolo di Chief Technical Operations Officer, apportando 30 anni di competenza nelle operazioni tecniche.
Inoltre, Justin Renz, attuale Chief Financial and Operations Officer, lascer脿 l'azienda entro la fine del 2025 o al completamento del passaggio a un nuovo CFO. Questi cambiamenti fanno parte della strategia di Ardelyx per posizionarsi nella sua prossima fase di crescita, dopo le recenti nomine di Mike Kelliher come CBO, Laura Williams come CPO e Jamie Brady come CHRO.
Ardelyx (NASDAQ:ARDX) anunci贸 cambios significativos en su Equipo de Liderazgo Ejecutivo. La compa帽铆a nombr贸 a Edward Conner, M.D. como Director M茅dico, aportando m谩s de 20 a帽os de experiencia en desarrollo cl铆nico y aprobaci贸n regulatoria. John Bishop, Ph.D. fue designado para el nuevo puesto de Director de Operaciones T茅cnicas, con 30 a帽os de experiencia en operaciones t茅cnicas.
础诲别尘谩蝉, Justin Renz, actual Director Financiero y de Operaciones, dejar谩 la empresa a finales de 2025 o tras la exitosa transici贸n a un nuevo CFO. Estos cambios forman parte de la estrategia de Ardelyx para posicionarse en su pr贸xima fase de crecimiento, tras recientes nombramientos como Mike Kelliher como CBO, Laura Williams como CPO y Jamie Brady como CHRO.
Ardelyx (NASDAQ:ARDX)電� 瓴届榿歆� 韺�鞐� 欷戨寑頃� 氤�頇旊ゼ 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞛勳儊 臧滊皽 氚� 攴滌牅 鞀轨澑 攵勳暭鞐愳劀 20雲� 鞚挫儊鞚� 瓴巾棙鞚� 臧�歆� Edward Conner, M.D.毳� 斓滉碃 鞚橂 毂呾瀯鞛�(Chief Medical Officer)搿� 鞛勲獏頄堨姷雼堧嫟. 霕愴暅, John Bishop, Ph.D.毳� 靸堧 鞁犾劋霅� 斓滉碃 旮办垹 鞖挫榿 毂呾瀯鞛�(Chief Technical Operations Officer)搿� 鞛勲獏頃橃棳 30雲勱皠鞚� 旮办垹 鞖挫榿 鞝勲靹膘潉 雿旐枅鞀惦媹雼�.
鞎勳毟霟� 順勳灛 斓滉碃 鞛 氚� 鞖挫榿 毂呾瀯鞛愳澑 Justin Renz電� 2025雲� 毵� 霕愲姅 靸堧鞖� CFO搿� 靹标车鞝侅溂搿� 鞚胳垬鞚戈硠臧� 鞕勲霅橂姅 鞁滌爯鞐� 須岇偓毳� 霒犽偁 鞓堨爼鞛呺媹雼�. 鞚措煬頃� 氤�頇旊姅 Ardelyx臧� 斓滉芳 Mike Kelliher毳� CBO, Laura Williams毳� CPO, Jamie Brady毳� CHRO搿� 鞛勲獏頃� 雿� 鞚挫柎 雼れ潓 靹膘灔 雼硠鞐� 鞝勲灥鞝侅溂搿� 雽�牍勴晿旮� 鞙勴暅 臁办箻鞛呺媹雼�.
Ardelyx (NASDAQ:ARDX) a annonc茅 des changements importants au sein de son 茅quipe de direction ex茅cutive. L'entreprise a nomm茅 Edward Conner, M.D. au poste de Chief Medical Officer, apportant plus de 20 ans d'exp茅rience en d茅veloppement clinique et en approbation r茅glementaire. John Bishop, Ph.D. a 茅t茅 nomm茅 au nouveau poste de Chief Technical Operations Officer, avec 30 ans d'expertise en op茅rations techniques.
De plus, Justin Renz, l'actuel Chief Financial and Operations Officer, quittera l'entreprise d'ici la fin 2025 ou apr猫s une transition r茅ussie vers un nouveau CFO. Ces changements s'inscrivent dans la strat茅gie d'Ardelyx pour pr茅parer sa prochaine phase de croissance, suite aux r茅centes nominations de Mike Kelliher en tant que CBO, Laura Williams en tant que CPO et Jamie Brady en tant que CHRO.
Ardelyx (NASDAQ:ARDX) hat bedeutende Ver盲nderungen im Executive Leadership Team bekannt gegeben. Das Unternehmen ernannte Edward Conner, M.D. zum Chief Medical Officer, der 眉ber 20 Jahre Erfahrung in klinischer Entwicklung und Zulassungsverfahren mitbringt. John Bishop, Ph.D. wurde in die neu geschaffene Position des Chief Technical Operations Officer berufen und bringt 30 Jahre Erfahrung in technischen Betriebsabl盲ufen mit.
Dar眉ber hinaus wird Justin Renz, der derzeitige Chief Financial and Operations Officer, das Unternehmen bis Ende 2025 oder nach erfolgreichem 脺bergang zu einem neuen CFO verlassen. Diese Ver盲nderungen sind Teil der strategischen Ausrichtung von Ardelyx f眉r die n盲chste Wachstumsphase, nach den k眉rzlichen Ernennungen von Mike Kelliher als CBO, Laura Williams als CPO und Jamie Brady als CHRO.
- Creation of new CTOO role demonstrates strategic focus on technical operations
- Appointment of experienced executives with decades of relevant industry expertise
- Orderly CFO transition with Renz staying through end of 2025 or until replacement found
- Departure of CFO Justin Renz after five years of service indicates significant leadership change
- Multiple concurrent leadership changes could create temporary organizational disruption
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer
Justin Renz, Chief Financial and Operations Officer, to transition out of the Company
WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc.聽(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs today announced changes to the Executive Leadership Team.
The company announced the appointment of Edward Conner, M.D. to the position of Chief Medical Officer. Dr. Conner is a seasoned biopharmaceutical executive with more than two decades of experience advancing innovative therapies through clinical development and regulatory approval across a number of therapeutic areas.
John Bishop, Ph.D. has been appointed to the newly established role of Chief Technical Operations Officer (CTOO), bringing more than 30 years of experience leading technical operations, quality assurance and chemistry, manufacturing and controls (CMC) regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTOO role and Dr. Bishop鈥檚 appointment reflects the growing and critical role technical operations plays in the long-term success of the company.
鈥淥ver the last year, we have carefully considered how to best position Ardelyx for its next phase of growth. We have welcomed executive team members who have deepened our leadership capabilities and breadth of expertise,鈥� said Mike Raab, Ardelyx president and chief executive officer. 鈥淎rdelyx is at an important stage of its evolution, and we have recruited leaders to help us achieve our ambitions. Leaders such as Mike Kelliher as Chief Business Officer, Laura Williams as Chief Patient Officer, Jamie Brady as Chief Human Resources Officer and now Ed Connor as Chief Medical Officer and John Bishop as Chief Technical Operations Officer will help us fully realizing the opportunities of our current business, building a robust pipeline and deliver on our vision of creating a healthier tomorrow for patients.鈥�
Ardelyx also announced that Justin Renz, Chief Financial and Operations Officer (CFOO), is expected to leave the Company. He will continue with the Company through the earlier of the end of this year or until Ardelyx has appointed and completed a transition to a new Chief Financial Officer.
Raab continued, 鈥淛ustin Renz has been a trusted leader at Ardelyx for the past five years. He has seen us through some of our biggest challenges and has helped shape our culture and the success that we have today. Justin has created a best-in-class finance organization at Ardelyx and has positioned us for success. I am thankful for Justin鈥檚 willingness to stay with us while we identify a successor and transition his responsibilities. I want to thank Justin for his partnership, leadership and friendship, and I wish him success in his future endeavors.鈥�
鈥淲hile I am stepping away from Ardelyx, I remain excited about the company鈥檚 future as it enters this important next phase of growth. It has been a privilege to serve as CFOO of Ardelyx, and I am truly honored to have built a talented, high performing team, to have partnered with my colleagues to achieve our shared successes, and to have brought relief to the many patients who have benefited from our medicines.鈥�
础产辞耻迟听础谤诲别濒测虫
Ardelyx聽was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs.聽Ardelyx聽has two commercial products approved in聽the United States, IBSRELA庐聽(tenapanor) and XPHOZAH庐聽(tenapanor).聽Ardelyx聽has agreements for the development and commercialization of tenapanor outside of the聽U.S.聽Kyowa Kirin commercializes PHOZEVEL庐聽(tenapanor) for hyperphosphatemia in聽Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in聽China聽with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in聽Canada. For more information, please visit聽聽and connect with us on聽,听听补苍诲听.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx鈥檚 current expectations regarding the date on which Justin Renz will transition out of the Company. Ardelyx undertakes no obligation to update or revise any forward-looking statements.
Investor and Media Contacts:
Caitlin Lowie
FAQ
Who is the new Chief Medical Officer of Ardelyx (ARDX)?
Why is Justin Renz leaving Ardelyx?
What is John Bishop's role at Ardelyx?
How many new executive appointments has Ardelyx made recently?
When will Justin Renz leave his position as ARDX's CFO?
